Triveni Bio Raises $65 Million Series C Financing to Expand Scope of First-in-Class Bispecific TRIV-573 Clinical Studies and Drive Next-Stage Company Growth

Triveni Bio Inc., a clinical-stage biotechnology firm focused on innovative antibody treatments for immunological and inflammatory disorders, has successfully raised $65 million in a Series C financing round. The funding, announced on June 17, 2026, was co-led by Ascenta Capital and Janus Henderson Investors, with significant participation from Deep Track Capital and existing investors. This capital infusion is intended to bolster the company’s pipeline expansion and facilitate the advancement of its clinical programs, particularly the Phase 2 clinical proof-of-concept trial for its lead candidate, TRIV-573, targeting atopic dermatitis.

The Series C funding marks a pivotal moment for Triveni Bio as it seeks to enhance its clinical development capabilities. TRIV-573 is a next-generation bispecific antibody designed to address the underlying causes of atopic dermatitis by dual-targeting the Th2 cytokine IL-13 and the kallikrein proteases KLK5 and KLK7, which are implicated in skin barrier dysfunction. The anticipated Phase 2 trial is expected to commence later this year, further validating Triveni’s commitment to tackling significant unmet medical needs in dermatological care.

The participation of Ascenta Capital and Janus Henderson Investors underscores the strategic interest in Triveni Bio's innovative approach to treating inflammatory disorders. Evan Rachlin, M.D., Co-Founder and Managing Partner at Ascenta Capital, will join Triveni's Board of Directors, bringing extensive industry experience to guide the company through its next growth phase. The involvement of seasoned investors is indicative of the confidence in Triveni's operational execution and its ability to advance drug candidates efficiently from concept to clinical trials.

Triveni Bio operates in a competitive biotechnology landscape where the demand for effective treatments for chronic inflammatory conditions is high. The company's focus on leveraging genetics-informed precision medicine positions it uniquely to address the complexities of diseases like atopic dermatitis. With TRIV-573 and its other pipeline candidates, Triveni aims to provide new therapeutic options that not only alleviate symptoms but also target the root causes of these conditions.

The successful fundraising round reflects broader trends in the biotechnology sector, where investor interest remains robust, particularly for companies developing novel therapies in areas with significant unmet needs. As Triveni Bio moves forward with its clinical trials, the outcomes will be closely monitored by investors and industry stakeholders alike, as they could have implications for the company's future valuation and the overall market for immunological therapies. The momentum generated by this financing round positions Triveni Bio to potentially disrupt existing treatment paradigms in atopic dermatitis and related disorders.